Detailed Information on Publication Record
2017
Amino Acid Profiling of Zinc Resistant Prostate Cancer Cell Lines: Associations With Cancer Progression
KRATOCHVÍLOVÁ, Monika, Martina RAUDENSKÁ, Zbynek HEGER, Lukas RICHTERA, Natalia CERNEI et. al.Basic information
Original name
Amino Acid Profiling of Zinc Resistant Prostate Cancer Cell Lines: Associations With Cancer Progression
Authors
KRATOCHVÍLOVÁ, Monika (203 Czech Republic, belonging to the institution), Martina RAUDENSKÁ (203 Czech Republic, belonging to the institution), Zbynek HEGER (203 Czech Republic), Lukas RICHTERA (203 Czech Republic), Natalia CERNEI (203 Czech Republic), Vojtech ADAM (203 Czech Republic), Petr BABULA (203 Czech Republic, belonging to the institution), Marie NOVÁKOVÁ (203 Czech Republic, belonging to the institution), Michal MASAŘÍK (203 Czech Republic, guarantor, belonging to the institution) and Jaromír GUMULEC (203 Czech Republic, belonging to the institution)
Edition
Prostate, Hoboken, Wiley-Blackwell, 2017, 0270-4137
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30202 Endocrinology and metabolism
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 3.347
RIV identification code
RIV/00216224:14110/17:00096422
Organization unit
Faculty of Medicine
UT WoS
000397496300005
Keywords in English
amino acid; aspartate; metabolomics; resistance; zinc
Tags
Tags
International impact, Reviewed
Změněno: 15/3/2018 17:02, Soňa Böhmová
Abstract
V originále
BACKGROUND: Failure in intracellular zinc accumulation is a key process in prostate carcinogenesis. Nevertheless, epidemiological studies of zinc administration have provided contradicting results. In order to examine the impact of the artificial intracellular increase of zinc(II) ions on prostate cancer metabolism, PNT1A, 22Rv1, and PC-3 prostatic cell lines—depicting different stages of cancer progression—and their zinc-resistant counterparts were used. To determine “benign” and “malignant” metabolic profiles, amino acid patterns, gene expression, and antioxidant capacity of these cell lines were assessed. METHODS: Amino acid profiles were examined using an ion-exchange liquid chromatography. Intracellular zinc content was measured by atomic absorption spectrometry. Metallothionein was quantified using differential pulse voltammetry. The content of reduced glutathione was determined using high performance liquid chromatography coupled with an electrochemical detector. Cellular antioxidant capacity was determined by the ABTS test and gene expression analysis was performed by qRT-PCR. RESULTS AND CONCLUSIONS: Long-term zinc treatment was shown to reroute cell metabolism from benign to more malignant type. Long-term application of high concentration of zinc(II) significantly enhanced cisplatin resistance, invasiveness, cellular antioxidant capacity, synthesis of glutathione, and expression of treatment resistance- and stemness-associated genes (SOX2, POU5F1, BIRC5). Tumorous cell lines universally displayed high accumulation of aspartate and sarcosine and depletion of essential amino acids. Increased aspartate/threonine, aspartate/methionine, and sarcosine/serine ratios were associated with cancer phenotype with high levels of sensitivity and specificity.
Links
MUNI/A/1365/2015, interní kód MU |
| ||
ROZV/20/LF/2015, interní kód MU |
|